Pharmaron Beijing Co Ltd
SZSE:300759
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
18.08
36.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Pharmaron Beijing Co Ltd
Pharmaron Beijing Co Ltd
Other Long-Term Assets
Pharmaron Beijing Co Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Other Long-Term Assets
¥953.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Other Long-Term Assets
¥2.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Other Long-Term Assets
¥548.8m
|
CAGR 3-Years
30%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Other Long-Term Assets
¥363.9m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
54%
|
|
|
Genscript Biotech Corp
HKEX:1548
|
Other Long-Term Assets
$172.1m
|
CAGR 3-Years
187%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Other Long-Term Assets
¥6.4m
|
CAGR 3-Years
134%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharmaron Beijing Co Ltd
Glance View
Pharmaron Beijing Co Ltd., a dynamic player in the biotech and pharmaceutical services sector, has carved a niche by capitalizing on the demand for comprehensive R&D services. Founded in 2004, the company emerged at a time when global pharmaceutical companies were grappling with skyrocketing research costs and the increasing complexity of drug development. Pharmaron offers a broad spectrum of services across the drug discovery and development pipeline, including laboratory services, chemistry, biology, and pharmacology, effectively monetizing its expertise by partnering with global pharmaceutical firms. By providing integrated solutions that cover the entire span of research, from preclinical development to commercial manufacturing, Pharmaron positions itself as an indispensable ally for companies aiming to streamline their product development journeys. The company’s revenue model thrives on long-term partnerships and collaborations with some of the industry's leading pharmaceutical and biotech firms. Using a client-centric approach, Pharmaron aligns its capabilities with customer needs, ensuring scalable and customizable service offerings. This close alignment not only enhances client satisfaction but also encourages repeat business, fostering a cycle of sustainable revenue growth. In recent years, Pharmaron has been expanding its geographical footprint and service capacity through strategic acquisitions and investments in state-of-the-art facilities and technologies, aiming to bolster its position in key markets across the US, Europe, and China. As the pharmaceutical landscape continues to evolve, Pharmaron leverages its robust R&D service portfolio and strategic alliances to maintain its growth trajectory amidst a backdrop of increasing globalization and technological advancement in the industry.
See Also
What is Pharmaron Beijing Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
953.7m
CNY
Based on the financial report for Sep 30, 2024, Pharmaron Beijing Co Ltd's Other Long-Term Assets amounts to 953.7m CNY.
What is Pharmaron Beijing Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
29%
Over the last year, the Other Long-Term Assets growth was 9%. The average annual Other Long-Term Assets growth rates for Pharmaron Beijing Co Ltd have been 13% over the past three years , 29% over the past five years .
You don't have any saved screeners yet
